Search filters
Filters
Clear All

Phase

  • 13
  • 1
  • 10
  • 6
  • 175
  • 206
  • 166
  • 1
  • 5
  • 200

Found 206 cc-cancer-center trials

A listing of cc-cancer-center medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 05423 A Phase I, Open-Label, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ONO-7018 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leuk

99 years and younger
All genders
Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints).
Learn More

S2104: A Phase II Randomized Trial of Postoperative Adjuvant Capecitabine and Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine

99 years and younger
All genders
The purpose of this study is to compare the usual approach (observation) to using capecitabine and temozolomide. We will enroll patients with High-Risk Pancreatic Neuroendocrine Tumors. We will utilize CIRB as the IRB of Record.
Learn More

UPCC 04424 A Phase 1 FirstinHuman Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV787 in Adult Subjects with Acute Myeloid Leukemia (AML)

99 years and younger
All genders
Please refer to Protocol Section1.1.1 (Objectives and Endpoints). Please refer to Protocol Section1.1.1 (Objectives and Endpoints). Please refer to Protocol Section1.1.1 (Objectives and Endpoints).
Learn More

CAB-101: A phase 1, open-label, safety and dosing study of autologous desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) in subjects with active, anti-DSG3, mucosal-dominant pemphigus vulgaris

99 years and younger
All genders
This research is being done to determine the maximum dose of an investigational drug called autologous desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) that can be safely given to patients with pemphigus vulgaris to target and kill only the B cells that are making the autoantibodies that attack DSG3.
Learn More

UPCC 06824:A Phase I/II Open Label Study to Evaluate the Safety, Cellular Kinetics, and Efficacy of AZD0754, a Chimeric Antigen Receptor (CAR) T-cell Therapy Directed Against STEAP2, in Adult Participants with Metastatic Prostate Cancer: APOLLO

99 years and younger
All genders
Please refer to Protocol Section 3 (Objectives, Endpoints, and Estimands). Please refer to Protocol Section 3 (Objectives, Endpoints, and Estimands). Please refer to Protocol Section 3 (Objectives, Endpoints, and Estimands).
Learn More

UPCC 06124: CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Br

99 years and younger
All genders
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either …
Learn More

UPCC 19424: A Modular Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 as Monotherapy or in Combination With Anticancer Agent(s) in P

99 years and younger
All genders
Please refer to Protocol Section 3 (Objectives, Endpoints, and Estimands). Please refer to Protocol Section 3 (Objectives, Endpoints, and Estimands). Please refer to Protocol Section 3 (Objectives, Endpoints, and Estimands).
Learn More

UPCC 07924: Phase 1, First-in-Human Study to Assess the Safety, Tolerability and Anti-tumor Activity of CDR404 in HLA-A*02:01 Participants with MAGE-A4 Expressing Solid Tumors

99 years and younger
All genders
Please refer to Protocol Section1.3 (Core Objectives and Endpoints). Please refer to Protocol Section1.3 (Core Objectives and Endpoints). Please refer to Protocol Section1.3 (Core Objectives and Endpoints).
Learn More

EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib alone in Patients with recurrent or persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial

99 years and younger
All genders
Cohort 1:Compare progression free survival of combination of olaparib and selumetinib to selumetinib alone in patients with RAS mutant ovarian cancer. Cohort 2:Compare progression free survival of combination of olaparib and selumetinib to selumetinib alone in patients with RAS mutant endometrial cancer.
Learn More

UPCC 13824: A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma

99 years and younger
All genders
The primary objective of the study is to compare V940 plus pembrolizumab to placebo plus pembrolizumab with respect to disease-free survival (DFS) as assessed by the investigator. The primary hypothesis is that V940 plus pembrolizumab is superior to placebo plus pembrolizumab with respect to DFS. We would like to rely …
Learn More
151 - 160 of 206